Suppr超能文献

胱氨酸尿症治疗反应不佳-慢性肾脏病的风险。

Cystinuria poorly responding to treatment - the risk of chronic kidney disease.

机构信息

Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine. Warsaw, Poland.

Independent Public Healthcare Center of the Ministry of Interior and Administration with the Warmia and Mazury Oncology Center in Olsztyn, Poland.

出版信息

Pol Merkur Lekarski. 2021 Feb 24;49(289):60-63.

Abstract

UNLABELLED

Cystinuria is the genetic condition for the increased excretion of cystine in the urine. Patients mainly suffer from afflictions related to the presence and passage of kidney stones. The currently available treatment methods include conservative treatment based on increased fluid intake, appropriate diet, medications and urological procedures. The causal treatment has not yet been invented.

A CASE REPORT

A patient case was described whose first symptomatic kidney stones appeared after the second year of life. Urinary cystine excretion was significantly increased - 25,431 μmol/1g creatinine (norm: 167-333 μmol/1g creatinine), which was also shown, but lower, in both parents of the patient. Despite the early initiation of therapy including low sodium diet, abundant hydration, alkalization, captopril and compliance with stringent restrictions, the level of urinary cystine excretion was still not within the normal range. There have been many modifications to the therapy and dose increases of drugs, but without visible results. The patient underwent several urological procedures, including: ESWL (Extracorporeal shock wave lithotripsy), URSL (Ureteroscopic lithotripsy), PCNL (Percutaneous nephrolithotomy) and open surgery to remove cystine deposits that were still produced in the kidneys. In addition, for many years the disease was complicated by recurrent urinary tract infections, underweight and lesions like epithelial metaplasia in the bladder. Renal parameters were repeatedly examined. Elevated results such as: serum creatinine 0.9 mg/dl, cystatin C concentration 1.10 mg/l, albumin-creatinine index 0.197, creatinine clearance 50.7 ml/min /1.73 m2 and eGFR 73 ml/min/1.73 m2 allowed for the diagnosis of chronic kidney disease before the age of 18. After many years of conservative treatment, only the introduction of thiopronine, still little known in Poland, reduced the level of cystine excreted in the urine. The inclusion of the drug reduced the tendency to produce kidney stones, which allowed to inhibit the progression of renal failure.

CONCLUSIONS

Despite many years of research and modern drugs, cystinuria is still a disease with which patients are associated for the rest of their lives. The ongoing research, along with attempts to understand the genetic and epigenetic mechanisms responsible for the emergence of mutations in the main genes causing the disease and the course of the disease, gives hope for finding a method of causal treatment for cystinuria.

摘要

背景

胱氨酸尿症是一种遗传性疾病,导致尿液中胱氨酸排泄增加。患者主要患有与肾结石的存在和通过相关的疾病。目前的治疗方法包括基于增加液体摄入、适当饮食、药物和泌尿科手术的保守治疗。因果治疗尚未发明。

病例报告

描述了一名患者,其首次出现症状性肾结石是在生命的第二年。尿胱氨酸排泄明显增加-25431μmol/1g 肌酐(正常值:167-333μmol/1g 肌酐),患者的父母也有,但较低。尽管早期开始治疗,包括低钠饮食、充足的水合作用、碱化、卡托普利和严格限制的依从性,尿胱氨酸排泄水平仍未在正常范围内。治疗方案已多次修改,药物剂量增加,但未见明显效果。患者接受了多次泌尿科手术,包括:体外冲击波碎石术(ESWL)、输尿管镜碎石术(URSL)、经皮肾镜取石术(PCNL)和开放性手术,以清除仍在肾脏中产生的胱氨酸沉积物。此外,多年来,疾病反复发作尿路感染、体重不足和膀胱上皮化生等病变。反复检查肾脏参数。升高的结果,如血清肌酐 0.9mg/dl、胱抑素 C 浓度 1.10mg/l、白蛋白-肌酐指数 0.197、肌酐清除率 50.7ml/min/1.73m2 和 eGFR 73ml/min/1.73m2,允许在 18 岁之前诊断为慢性肾脏病。经过多年的保守治疗,只有在波兰鲜为人知的硫普罗宁的引入,降低了尿液中胱氨酸的排泄水平。该药物的加入减少了肾结石形成的趋势,从而抑制了肾功能衰竭的进展。

结论

尽管进行了多年的研究和使用现代药物,胱氨酸尿症仍然是一种患者终身与之相关的疾病。正在进行的研究,以及试图了解导致疾病主要基因发生突变的遗传和表观遗传机制以及疾病过程,为寻找胱氨酸尿症的因果治疗方法带来了希望。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验